SCHEMBL717420

SCHEMBL717420

CC(NC(=O)O)c1cc2cccc(Cl)c2nc1N1CCN(CC(=O)N(C)C)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.44
P2RX3 P56373 1/20 0.37
BRD4 O60885 1/20 0.37
CACNA2D1 P54289 2/20 0.36
CACNA1B Q00975 2/20 0.36
CACNB1 Q02641 2/20 0.36
CACNA1C Q13936 2/20 0.36
KDM4E B2RXH2 2/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
RAB9A P51151 1/20 0.36
P2RY12 Q9H244 3/20 0.36
SOS1 Q07889 1/20 0.36
KDR P35968 1/20 0.35
IGF1R P08069 1/20 0.35
KCNH2 Q12809 1/20 0.35
AURKA O14965 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716003 0.91 PIK3CD (0.53) PIK3CDP2RX3KDM4ENPC1LMNA
SCHEMBL716017 0.87 PIK3CD (0.44) PIK3CDP2RX3CACNA2D1CACNA1BCACNB1
SCHEMBL716018 0.87 PIK3CD (0.44) PIK3CDP2RX3CACNA2D1CACNA1BCACNB1
SCHEMBL716164 0.84 AKT1 (0.40) PIK3CD
SCHEMBL715149 0.83 PIK3CD (0.47) PIK3CDP2RX3LMNAIGF1RKCNH2
SCHEMBL715148 0.83 PIK3CD (0.47) PIK3CDP2RX3LMNAIGF1RKCNH2
SCHEMBL715607 0.83 CNR2 (0.43) PIK3CDP2RX3KDM4EP2RY12ALDH1A1
SCHEMBL717045 0.82 PIK3CB (0.40) PIK3CDKDM4EMEN1KMT2AALDH1A1
SCHEMBL716476 0.81 CNR1 (0.40) KDM4ENPC1LMNARAB9AMEN1
SCHEMBL713901 0.81 AKT1 (0.43) KDM4EP2RY12SOS1ALDH1A1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 PIK3CD 12/4885P2RX3 653/4885BRD4 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.